CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS) today reported financial results for the quarter ended September 30, 2016 and provided an update on recent accomplishments and upcoming events.
“With the dosing of the first patient in our first clinical study, a Phase 2 trial of SY-1425 in genomically defined AML and MDS populations, we rapidly advanced the broad promise of our gene control platform into the clinic in less than four years since Syros’ inception,” said Nancy Simonian, M.D., Chief Executive Officer of Syros.
